Strohal – 7/2006
CURRICULUM VITAE
Robert Strohal, MD
Associate Professor of Dermatology, Head
______________________________
Address
business:
home:
Dept. of Dermatology and Venerology
St. Antoniusstr. 12/3
Federal University Teaching Hospital Feldkirch
A-6800 Feldkirch
Carinagasse 47
Austria
A-6800 Feldkirch
email: strohal@a1.net
Austria
mobile +43/664/1142140
e-mail: robert.strohal@lkhf.at
Phone+43/5522/303-9121,1200
Fax: +43/5522/303-769121
1
Strohal – 7/2006
Date/place of birth:
Marital status:
December 23, 1959; Bludenz, Austria
married, 3 children, Sophie-Patricia, Tobias-Michael, Simon Alexander
 Education/Pre-doctoral Experience
1985 - 86
Theses at the Institute of General and Experimental Pathology,
University of Innsbruck Medical School, title: Murine systemic
Lupus erythematosus: cDNA cloning and sequencing of heavy and
light chains mRNA of a monoclonal anti-DNA autoantibody
1987
MD, University of Innsbruck Medical School, Innsbruck, Austria
 Post-doctoral Experience
1988
Start of the residency in Dermatology at the Department of
Dermatology I., University of Vienna School of Medicine
1988/1990
Research visits at the NIH – lmmunology and Dermatology Branch,
Bethesda, USA; Drs S. Katz/J. Stanley
1991
Start of own research group "molecular immunology of
melanoma" at the Division of Immunology, Allergy and Infectious
Diseases, University of Vienna School of Medicine
1995 -1995
Special training in plastic surgery at the Division of Plastic
Surgery, Department of General Surgery, University of Vienna School
of Medicine
1994/1995
Qualification as board-certified Dermatologist, Senior
Physician/Attending at the Division of Immunology, Allergy and
Infectious Diseases, Department of Dermatology, University of
Vienna School of Medicine (Head Division: Prof.G.Stingl, Dept.-Chair:
Prof.K.Wolff)
1999
Venia legendi, Associate Professor of Dermatology at the
Department of Dermatology, University of Vienna School of Medicine
2000
Tenure at the same Department
2000
Sabbatical I.: Dystrophin as potential early tumor marker in nonmelanoma and melanoma skin cancer (Cooperation: Prof. Bittner,
Dept. of Anatomy II, Univ. of Vienna School of Med.)
2001
Sabbatical II.: Melanoma antigen transduced autografts as a new form
of tumor vaccine, European Commission Marie Curie Fellowship Cat.
40 for experienced researchers (Cooperation: Dr. De-Luca, IDI
Farmaceutici, Rom)
2002
Establishment of a new Clinical Department of Dermatology and
Venerology as Head of the Department, Federal University Teaching
Hospital Feldkirch, Austria
2006
Establishment of a new research Institute (Vorarlberg Institute
for Dermatologic Investigation and Treatment, VIDIT – a department of
the VIVIT Research Center, Feldkirch, Austria) as Head of the
Institute
2
Strohal – 7/2006
 Additional certificates

Board Certification of the Austrian Society of Dermatology and Venerology,
15.11.1995

Diploma, Dermatohistopathology; Austrian Society of Dermatology, 1994

Diploma, Testing physician for clinical phase-3-4 trials; Austrian Society of Clinical
Pharmacology, 1996

Diploma, Dermatoscopy, Austrian Society of Dermatological Post-Doctoral
Education, 1996

Diploma, Hospital Management, Austrian Medical Association; 11/1998-7/1999

Diploma, medical court expert, Austrian Medical Association; 10/2001
 Scientific awards and scholarships

Scholarship of the University of Innsbruck Medical School for excellent studies.
1984/1985.

Otto Westphal Thesis-Award of the German Society of Immunology 1985/1986.
October 1, 1987; Ulm, Germany

Emil-Boral Scholarship of the Emil-Boral Foundation. 1/1/87 - 12/31/1988; Zurich,
Switzerland

Travel Grant of the Japanese Society of Investigative Dermatology. Second
Tricontinental Meeting JSID, SID and ESDR, October 28-31, 1993; Kyoto, Japan

AESCA-Award of the Austrian Society of Dermatology 1994. December 2, 1994;
Vienna, Austria

Unilever-Award of the Austrian Society of Dermatology and Venerology 1998;
November 29, 1998; Linz, Austria

Marie Curie fellowship for experienced researchers - an academia-industry
exchange programme (MCFI-2000-001668): Melanoma antigen transduced
autografts as a new form of tumor vaccine. European Commission, Improving Human
Potential, 7/2001.
 Editorial/Board Memberships

Vienna Medical Association, Assistant Executive Head of the Physicians group
"Dermatology and Venerology", responsibility: Curia for employed physicians, 1999
- 2002.

European Assotiation of Dermato-Oncology (EADO), Secretary and Board
Member, since 10/03

Austrian Society of Dermatology and Venereology (ÖGDV), Associated Board
Member, since 5/05

Working Group “Biologics in Dermatology” of the Austrian Society of Dermatology
and Venereology (ÖGDV), Working Chair and Board Member, since 5/05

Society of Physicians Vorarlberg, president, since 9/04
3
Strohal – 7/2006

Wound.net.Vorarlberg - a cooperative quality assurance, study and teaching group
strategically covering all wound-related facilities (hospital departments, doctors in free
practice, community nursing organizations and nursing homes in the Federal State of
Vorarlberg), president, since 10/03

Vorarlberg Medical Association, Vice Executive Head of the Physicians group
"Dermatology and Venerology", responsibility: Curia for employed physicians, 5/2003.

Österreichische Krebshilfe, Sektion Vorarlberg (Cancer-AID Society), Board
Member, since 2/04

Drug Counseling Board of the Federal Academic Hospital Feldkirch, Board
member, since 2/04

Interdisciplinary Tumor Board of the Federal Academic Hospital Feldkirch, Board
member, since 2/04

Jatros Dermatologie: Member of the Journal´s Scientific Board, since 11/03

Medical Update Dermatology, a scientific publishing Series, Editor, Up-date,
Vienna, Austria, since 1/06

Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Board
member, since 3/2006
 Advisory Boards/Expert Groups
 Organizer/Co-Chair of the Austrian “Enbrel in Psoriasis and Psoriasisarthritis”
Advisory Board, Wyeth Lederle Pharma, since 3/03.

Member of the Austrian Advisory Board for “The role of Alefacept in Psoriasis”,
Biogen Inc. 5/02 – 4/04.

Member of the Austrian Clinical Experts Group (Dermatologists/Pediatrician) for
“Protopic in atopic eczema”, Fujisawa Group, since 11/02.

Member of the Clinical Experts Group for “The role of topical steroids in
Dermatology”, Up/date Europe, 2/03 – 1/05.

Member of the Austrian Advisory Board (Dermatologists/Rheumatologists) for “The
role of Infliximab in Psoriasis and Psoriasisarthritis”, Schering Plough/AESCA,
since 8/03.
Member of the “Raptiva and Psoriasis” Austrian Clinical Expert Group, Serono,
since 3/04
The Group for Research and Assessment of Psoriasis and Psoriasis Arthritis –
GRAPPA, USA/Europe (www.grappanetwork.org), member, since 11/04





Member of the European Dermatology Expert Panel – Wyeth International, since
4/05, Meetings: April 15th – 17th, 2005, Paris; June 17th – 18th, 2005, Rome; October
15th – 16th, 2005 London, February 23th – 24th, 2006, Barcelona.
Organizer/Co-Chair of the Austrian “Humira and Psoriasisarthritis” Advisory Board,
Abbott Pharma, since 11/05.
Member of the Austrian Dermatology Advisory Board, “Infliximab in Dermatology”
AESCA Pharma, since 11/05.
4
Strohal – 7/2006
 Teaching Responsibilities
 Molecular Biology and Dermatological Clinics. Medical University Vienna, Vienna
Austria. Course N° 529100

Specifics in Dermatology. Post-Graduate Teaching Series for MDs during their
Internship, Feldkirch, Austria

General Dermatology. Federal Academic Hospital of Feldkirch, School of Nursing,
Feldkirch Austria.

Geriatric Dermatology. Post Graduate Diploma Course for Geriatric Medicine,
Austrian Association of Physicians, Schloß Hofen Lochau, Austria
 Review Responsibilities
 Journal of Investigative Dermatology (JID)
 Applied Microbiology
 DEBRA Europe

Duhrig Böhler Award, panelist, since 9/04

Award of the Association of Physicians in Vorarlberg, panelist, since 11/04

Dermatological Expert in Court
 Elected Memberships - Clinical/Scientific Societies

Austrian Society of Dermatology and Venerology - ÖGDV

Society of Dermatological Research - ADF (Germany)

Society of Physicians, Vienna

Society of Physicians, Vorarlberg

German Dermatological Society - DDG;

European Society of Dermatological Research – ESDR

Austrian Society of Immunology and Allergy – ÖGAI

Marie Curie Fellowship Association – Platform of the European Commission for
scientists having received a Marie Curie Fellowship

Working Group for Occupational Skin Diseases (ABD) of the German Dermatological
Society
 Design and Lead of Multicentre-Studies

ACTICOAT - the human study. Smith + Nephew International, London, GB. Doublecenter Austrian trial, datacenter Dept. of Dermatology, Federal Academic Hospital of
Feldkirch with Dept. of Dermatology Wilhelminenspital Vienna. 11/2002 - 8/2003.

Pan-Austrian in-use study “Enbrel in Psoriatic Arthritis” performed by WyethLederle Pharma, 10/03 – 2/04

Design of a pan-Austrian in-use study for Dermatologists in private practice:
“Combination therapy of Vitiligo with Vitix and UV-B narrow band”, Sanova
Austria, 4/04-3/05

Pan-Austrian in-use study “Raptiva in Psoriasis” performed by Serono, start 10/04
5
Strohal – 7/2006

European ACTICOAT Trial (CE/023/AC3): An open labeled multicentre study to test
the barrier properties of ACTICOAT on MRSA colonized external acute and chronic
wounds. 6 European centres, start 9/05-
 Research Projects

In-situ Immunophänotypisierung des monoklonalen entzündlichen Infiltrats beim
kutanen Melanom. Commission of Cancer Research, University of Vienna Medical
School. 12/1/92 - 11/30/93

Molekulare Studien zum Genrepertoire und Polymorphismus des T -Zell Rezeptors
Tumor-infiltrierender Lymphozyten im malignen Melanom. Project No. 4568 of the
Austrian Federal Bank. 5/1/93 - 5/30/95

Über Selektivität und Zeitkinetik der Transkription/Expression Melanom-assoziierter
Tumor-Abstoßungsantigene (tumor rejection antigens) und Möglichkeiten ihrer
Regulation in-vitro und in-vivo. Project No. 5562 of the Austrian Federal Bank.
12/1/95 - 10/1/97

Molekulare Studien zur Onkogenese des malignen Melanoms. Commission of Cancer
Research 4/1/96 - 3/31/98

Comparative studies on the antitumor activities of Interferon-α2b and mono-pegylated
Interferon- regarding their immunomodulating and antiproliverative effects on human
melanocytes and melanoma cells. Aesca Inc. Austria. 10/1/1998 -12/31/1998

Studien zur Klonalität primärer und metastasierender Melanome mittels Analysen
zum Expressionsmuster Melanom-assoziierter Antigene. Hochschuljubiläumsstiftung
der Stadt Wien, Project No. 54/98.12/1/1998 - 12/31/1999

Interferon- als potenter Stimulator der Tumorantigen, HLA und CD80 Expression
beim malignen Melanom: Phenotypische Analysen und funktionelle Implikationen.
Project No. 7583 of the Austrian Federal Bank. 1/1/99 - 3/1/00

Molekulare Studien zur Relevanz von Melanom-assoziierten Antigenen als
potentielle Tumorvakzine. Universitätspreis der Wiener Wirtschaft. 2/11/99 -1/30/00

Melanoma antigen transduced autografts as a new form of tumor vaccine (in
cooperation with IDI Farmaceutici, Rom). European Commission, Improving Human
Potential, 7/01 - 1/02

DERM-OCC - Austrian Mineral Oil Association (OMV) Pilot study (assessement of
1470 industrial workers). OMV Inc., 1/01 - 12/01

Dystrophin - a new potential biomarker for the malignant transformation of epithelial
and melanocytic tissues. Federal Ministery of Education, Science and Cultural Affairs.
10/00-3/02.

In vitro-pilot study of ACTICOAT® as new anti-MRSA barrier or therapeutic option for
external critically MRSA colonized wounds. Smith + Nephew Austria, 4/02 - 6/02.

Intron-A (Peglntron® ) low dose treatment in patients with malignant melanoma of
tumor thickness > 1.5 mm, AESCA Austria, in-use study, start 4/02 – 12/03

Intron-A (Peglntron® ) high dose treatment in patients with malignant melanoma in
stages IIB – III (AJCC-2002), AESCA Austria, in-use study, start 4/02-

Sensitivity and specificity of the European standard patch test formulations – a
comparative approach. BRIAL allergen gmbH, 8/02 - 4/03.
6
Strohal – 7/2006

DERM-OCC II - Evaluation, development and implementation of skin protection
standards for chemical industries, Austrian Mineral Oil Association (OMV), 5/03-2/06

Imiquimod open trial for actinic keratosis and basal cell carcinoma: a clinical and
immunohistochemical study. 3M Austria, 10/02 – 9/04

DERM-OCC - Suchard-Jakobs, Bludenz, Austria, March 2003

Silver Dressings and MRSA – a comparative microbiological in-vitro trial. Smith and
Nephew, UK, start 11/03-4/04

Alopecia areata - Pimecrolimus/Tacrolimus open labeled comparative study, 1/03 –
5/04

Alefacept and Psoriasis, Biogen Austria, in use study 10/03 –7/04

Silver Dressings and MRSA – a comparative microbiological in-vitro trial. Smith and
Nephew, UK, start 11/03-4/04

Protopic-Patch – Sensitivity of Epicutan-patch test reactions in Tacrolimus-loaded
skin. Fujisawa Austria, start 1/04-11/05.

Lamisil and Onychomycosis, Novartis Austria, in-use study, 6/04 – 10/04

Enbrel and Psoriasis Arthritis, Wyeth Austria, in use study 1/04 – 7/04

Elidel and AD, Novartis Austria, in-use study, 1/04 – 5/04

Randomized, multicenter, open label study to compare the efficiency and tolerability
of pegylated--2a (PEG-IFN) to “low dose” interferon--2a in patients with malignant
melanoma in stages IIA (T3a) – IIIB (AJCC-2002), ADO multicenter trial Germany,
Switzerland, Austria. start 8/2004-

A 22-week randomized, multicenter, parallel-group, double-blind study to compare a
pimecrolimus 1% (Elidel) twice daily maintenance dosing regimen to a once daily
maintenance dosing regimen in the management of atopic dermatitis in pediatric
subjects. Novartis International. 9/04 – 3/05

UV-light workplaces: Evaluation of dangers, biological read-out, development and
implementation of security measures. Swarovsky Triesen, Liechtenstein, start 5/0411/05.

The importance of hypersensitivity reactions against silicone for patients with cochlea
implants. Cooperation project within the KMT cluster Tyrol, Austria, Medel Inc. Austria
and Prof. Wick (Inst. for Patho-physiology, Univ. Innsbruck). start: 4/05-

CLEAREST: Continuous versus Intermittent Long-Term Etanercept therapy: a
randomized efficiency and safety trial in psoriasis. Protocol number 0881A6-101764,
Wyeth International Philadelphia, USA, start 3/05-

A multicentre, open-label phase IIIb/IV study of subcutaneously administered
efalizumab in the treatment of adult patients with moderate to severe chronic plaque
psoriasis who have failed to respond to, or who have a contraindication to, or are
intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA.
Serono Head Quarters Swizerland, start 6/05-

An open-label, randomized efficiency and safety study of Infliximab versus
Methotrexate in the treatment of moderate to severe psoriasis. Protocol number
P04271, Schering Plough International, start 10/05-

Rare genetic skin diseases: advancing diagnosis, management and awareness
through a European network. Acronym: GENESKIN, Proposal N° 512117, Concerted
7
Strohal – 7/2006
Action of the European Commission LSH 2003.2-1.1-7, Consortium: 30 partners from
12 different European countries, start 7/05
Bexaroten Gel and Mycosis fungoides stage I - intention to treat study, Zeneus
Pharma Europe, 6/04-1/06

Randomized, multicenter phase Ill trial comparing adjuvant treatment with Peglntron
36 months versus Intron A over 18 months in melanoma AJCC stage II patients.
EADO - 9 European countries trial. 6/03 - 1/06.

The anti-microbial effect of the photodynamic, laser-based therapy: a pre-clinical invitro study. 12/05 – 1/06. Sponsor: Helbo, Photodynamic Systems.

DERM-OCC II - Evaluation, development and implementation of skin protection
standards for chemical industries, Austrian Mineral Oil Association (OMV), 5/03-2/06

A combinational regimen of Vitix and UV/B narrow-band in Vitiligo patients. An openlabeled, intention to treat study, Sanova Austria. 2/04-3/06

Development of new sun-screen preparations. In cooperation with Plantapharm
Austria and Plegé Cosmetics Austria, 5/03-3/06

DERM-OCC, Suchard-Jakobs – A third year follow-up study, Bludenz, Austria, May
2006.

Efficacy and safety of Psorcutan-beta® as initial treatment and Psorcutan® ointment
as follow-up treatment of psoriatic lesions. Intendis Austria, in-use study, 2/06 – 5/06

Efficacy and safety of Tagretin® in the treatment of cutaneous T-Cell Lymphoma
patients, in-use study, Zeneus Pharma Germany, start 5/06 – 3/07

BIOMED – Establishment of a Vorarlberg Competence Center for Biomedical
Diagnostics and Research, EFRE Grant by the European Commission and the
Government of Vorarlberg, Consortium: Prof. Drexel, Head of the Department of
Medicine and Director of VIVIT, Dr. Lang, Head of the Division of Oncology, Dept. of
Medicine and Prof. Simma, Head of the Department of Pediatrics, University
Teaching Hospital of Feldkirch and VIVIT, start: 4/06
 Orqanisation and Co-Organisation of Meetings/Symposia

Satellite Meeting: B-cells and autoimmunity: New concepts and therapeutic
perspectives, IUIS-SSI, International Advisory Board, 19-21 July, 2001, Bergen
Norway.

Symposium "Malignant Melanoma - update", Society of Physicians Vorarlberg,
26.4.2003, 8:30 - 12:30, Feldkirch, Austria.

Enbrel – from the Rheumatoid Arthritis to Psoriasisarthritis. Wyeth Symposium.
In cooperation with Wyeth Inc., Chair and Lecture, 4.9.2003, Hotel Marriott Wien.

CURRICULUM Type I Allergy, Diagnosis, Therapy and Hands-on Workshop. In
cooperation with Prof. Dr. N. Reider, Dept. Dermatology, University of Innsbruck
School of Medicine, Dr. Elsässer, Dept. of Otology, Federal Academic Hospital of
Feldkirch and ALK-Pharma, Austria, 29.11. 2003, Dornbirn and 5.11.2003 Innsbruck,
Austria.

Diabetic foot syndrom – an interdisciplinary challenge. Symposium, S+N
Academy, March to June, 2004, 9:00 a.m. – 16:30 p.m., Vienna, Graz, Salzburg and
Innsbruck, Austria
8
Strohal – 7/2006

Multidisciplinary Symposia, Seminars, Lectures by the Society of Physicians
Vorarlberg. 9/2004 – 8/2006. The Vorarlberg Medical Association has delegated the
organisation of continuous medical education for all physicians working in the Federal
State of Vorarlberg to the Society of Physicians Vorarlberg. Consequently, the
Society of Physicians is organizing 1-3 educational events for all medical disciplines
per month

DERM-OCC III/Phase 1: Teaching Symposium “Train the Trainers” – Training
activities with regard to skin protection measures for all workers in the Austrian
Mineral Oil Association (OMV), Tuesday 22nd of February, 2pm – 7:30pm, Federal
Academic Hospital in Feldkirch, Austria.

Award of the Duhrig-Böhler Prices and Honorary Lecture by Dr. Wöß. Annual
Meeting of the Society of Physicians Vorarlberg, June 2nd , 2005, Feldkirch,
Austria

Slowakien Teaching Symposium on the use of Etanecept in Psoriasis and
Psoriasis Arthritis. In cooperation with Wyeth Inc., Chair and Lecture, 3.12.2005,
Bratislawa, Slowakia.

The concept of local MRSA management. Presentation and Chair. Kick-off Meeting
of the European ACTICOAT Trial (CE/023/AC3): An open labeled multicentre study
to test the barrier properties of ACTICOAT on MRSA colonized external acute and
chronic wounds. , 24-25.2.2006, Vienna, Austria.
 Invited Lectures

Are autoantigens encoded in the immunoglobulin loci ? V.Winter Round-Table
Conference on Controversial lmmunology, April 25, 1987; Kühtai, Austria

Die molekulare Genetik als Werkzeug der dermatologischen Klinik. Guestlecture at
the Dept. Dermatology, Univ. of Erlangen School of Medicine, February 19,
1992; Erlangen, Germany

The T -Cell receptor repertoire of Iymphocytes infiltrating cutaneous melanoma is
predominated by Va specificities present in T -cells of normal skin. Second
Tricontinental Meeting of the SID, JSID and ESDR, October 30, 1993; Kyoto,Japan

Subkorneale pustulöse Dermatose (Sneddon-Wilkinson) mit isolierter IgA-K
Paraproteinämie. Annual Meeting of the Austrian Society of Dermatology and
Venereology, Dezember 2-4, 1994; Vienna, Austria

Genetische Aspekte des Melanoms. Scientific Symposium of the Society of
Physicians in Vienna: Zum Stellenwert genetischer Faktoren in der Onkologie.
May 3, 1995; Vienna, Austria

CMV und Herpesvirusgruppe: Potentielle agonistische und antagonistische
Interaktionen im Rahmen der HIV-lnfektion. Scientific Symposium of the Austrian
AIDS-Society; November 11, 1995; Hotel Plaza Vienna, Austria

Immunotherapy of malignant melanoma. 4th GCC International Conference of
Dermatology and Venereology; March 4-6, 1997; Kuwait City, Kuwait

New therapeutic approaches in the treatment of malignant melanoma. 4th
9
Strohal – 7/2006
International Congress on Dermatology and Leprosy, October 8-10, 1997;
Teheran, Iran

Der Ausschlag - Ein arbeitsmedizinisches Problem? Lecture - Center of Industrial
Medicine of the Red Cross Organisation, May 14, 1998; Vienna, Austria

Qualitative und quantitative Analysen der in-situ Immunantwort des malignen
Melanoms. Guestlecture at the Dept. Dermatology, Univ. of Erlangen School of
Medicine, June 16, 1999; Erlangen, Germany

Wieviel Wirkkosmetik braucht der Mensch. HAGE-III, Joint Meeting of stakeholders and experts in the field of cosmetology, February 23, 2001; Hannover,
Germany

Erfahrungsbericht eines Evaluators. BIT-Symposium: European Commissionfunded research, Ludwig-Bolzmanngesellschaft, 18. July 18, 2001,
Raiffeisenzentralgebäude, Vienna.

Evaluation of Proposals, Kick-off meeting TRAIN-NET, September 14, 2001,
Budapest, Hungary.

Security, the doctors view - or - Discover the human being, Annual Meeting
Arbeitsschutzausschuss, November 6, 2001, OMV Headquarter, Vienna.

Dermatology in General Medicine, Inauguration Lecture, March 4, 2002, Federal
Academic Hospital Feldkirch, Feldkirch Austria.

Die schwere Akne als therapeutische Herausforderung. Roche Seminar, May 23
and November 25,2002, Dornbirn, Austria.

Braun sein - und trotzdem gesund? Health Day Initiative HLW Rankweil, May 24,
2002, Rankweil, Austria.

Neurodermitis und Psoriasis - Pathogenese, Klinik, therapeutische Möglichkeiten.
Meeting of the Vorarlberg Society of Pharmacists, June 26, 2002,Dornbirn,
Austria.

Die klinische Dermatologie - ein neues Gesundheitsangebot in Vorarlberg.
Association of Practitioners and Family Doctors, July 4, 2002, Bludenz, Austria
and October 13, Bregenz, Austria.

Silver Technology - New Developments and Perspectives. Annual Report Meeting
of Smith & Nephew Austria, January 16, 2003, Vienna, Austria.

Acticoat as potent barrier against MRSA. John Boswick Symposium on Burn and
Wound Management, Invited guest to the Expert Group Meeting, February 17, 2003,
Maui, Hawaii, USA.

Wound management in General Medicine, Introductionary lecture,
Educational Wound Care Symposium, March 11, 2003, Bregenz, Austria.

New therapeutic options for atopic eczema. Lecture for family doctors, March 27,
2003, Dornbirn, Austria.

Tatoos and allergologic implications. 7th Round table Meeting on Allergology,
March 3rd , 2003, Innsbruck, Austria
10
Strohal – 7/2006

Acticoat as new barrier and/or therapeutic option in MRSA colonized wounds.
Annual Meeting of the Austrian Wound Association, April 3, 2003, Innsbruck,
Austria.

Biologicals as new therapeutic option for severe Psoriasis. Guest lecture Vorarlberg
Association of Dermatologists, May 15, 2003, Dornbirn, Austria.

Acticoat and MRSA, or, how to expand markets. KOL – Lecture at the “Best practice
Meeting” Smith and Nephew International, May 20, 2003, Pisa, Italy.

Basal Cell Carcinoma. Lecture at the 12. Salzburger Therapiegespräche, ÖADF,
June 20, 2003, Mondsee, Austria.

The spectrum of Academic Dermato-Venerology, Rotary evening, August 19th, 2003,
Feldkirch, Austria.

Psoriasisarthritis – update. Enbrel – From the Rheumatoid Arthritis to
Psoriasisarthritis. Wyeth Symposium, 4.9.2003, Hotel Marriott, Vienna Austria

Nanokristalline Silbermembranen und MRSA. Annual Infection control round table
meeting of the ÖGKV and ÖGHMP, 16.9.2003, General Hospital Vienna, Austria.

The Clinical Spectrum of Dermato-Venerology. Association of Practitioners and
Family Doctors, September 22, 2003, Hard, Austria

Skin protection and the food industry, Suchard-Kraft Food, October 23, 2003,
Lörrach, Germany.

The multiple images of Imiquimod in Dermato-Venerology. Seminar Dialog Haut,
Pelpharma, October 10th, 2003, Venice, Italy.

Imiquimod and non melanoma skin cancer. EADO Satellite Symposium at the
Annual Meeting of the European Assotiation of Dermatology and Venerology,
15.10.2003, Barcelona, Spain.

Wound.net@vorarlberg - a new dimension in wound care. Invited lecture. 5th Update
and Advances in Wound Care, January 27th, 2004, Arosa, Switzerland.
S&N Dystrophic Epidermolysis Bullosa Advisory Board: Invited Guest, Meeting
February 2nd , 2004, Henley Park Hotel, Washington DC, USA


Sun without remorse. Rotary-evening, March 2nd, 2004, Feldkirch, Austria.

Ist die Sonne unser Freund oder Feind. Feldkircher Physician´s Seminars. April 7th,
2004. Feldkirch Austria

DERM-OCC – a new prevention and security concept for the industry. April 16th ,
2004. Invited lecture at OMICRON Inc., Klaus, Austria.

Setting new benchmarks for HAI and MRSA, Invited lecture, Symposium Series
“MRSA – a topical issue”, S+N Academy, April 27th – 29th, 2004, 9:30 am – 5:00
pm, London, Birmingham and Glasgow, UK.

Sun without remorse and Sexually transmitted disease, Lectures at the
Pädagogisches Institut des Landes Vorarlberg, 15:00 – 18:00, May 4th, 2004,
Feldkirch, Austria

Dermatology and Microbiology. Invited lecture. S+N Academy: Diabetic foot
syndrom – an interdisciplinary challenge. May 22th , 2004, 9:00 a.m. – 16:30 p.m.,
Vienna, Austria
11
Strohal – 7/2006

Dermatological slide show of the Department of Dermatology, Federal Academic
Hospital of Feldkirch. Lecture, Vorarlberg Association of Dermatologists, May 25,
2004, Feldkirch, Austria

Acticoat dressings as an efficient MRSA barrier: a new solution to an increasing
problem. Dressed for success – the role of dressings in reducing the risk of
infection. Exhibitor Symposium at the Association for Professionals in Infection
Control and Epidemiology (APIC 2004). Monday June 7th 2004, 7:00 pm, Phoenix
Aricona, US

Anaphylaxis. Post-graduate Training Program for Physicians. Thursday June 17th
2004, Feldkirch, Austria

Paradigmen der Externatherapie. Invited Lecture, Center of Occupational Medicine,
Austrian Mineral Oil Association (OMV), June 22nd, 2004, Schwechat, Austria.

Dermatology and Microbiology. Invited lecture. S+N Academy: Diabetic foot
syndrom – an interdisciplinary challenge. June 26th , 2004, 9:00 am, Innsbruck,
Austria

Acticoat and MRSA. Plenary lecture at the World Union of Wound Healing
Societies S+N Satellite Meeting, Friday July 9th, 2004, Paris, France

Weaknesses and strengths of Imiquimod in epithelial skin cancers – the clinician´s
view. Plenary lecture, Symposium Forum Biotechnology, International Skin Cancer
Congress, Thursday July 22nd, 2004, Zurich, Switzerland.

Rational for the development of a new PEG-Intron formulation. EADO Study Group
Meeting, International Skin Cancer Congress, Friday July 23nd, 2004, Zurich,
Switzerland.

Setting new benchmarks for HAI and MRSA. Invited Lecture, Symposium Series
“MRSA – a topical issue”, S+N Academy, September 28th and 30th, 2004, 9:30 am
– 5:00 pm, Newcastle and Manchester, UK.

Silver technology – from the bench to the Clinics. Invited Series of Lectures, S+N
Academy, October 25th – 29th, 2004, 2 Lunch and 4 Dinner Meetings, Los Angeles,
Chicago, Atlanta, New York and Washington, USA.

Change of paradigms in the treatment of atopic eczema. Educational Lecture for
Dermatologists and Pediatritians, November 4th, 2004, 7 pm Bregenz, Austria.

Imiquimod and non-melanoma skin cancer. EADO Satellite Symposium at the
Annual Meeting of the European Assotiation of Dermatology and Venerology,
17.11.2004, Florence, Italy.

Stigmata of the Skin. First Vorarlberg Skin Caring Day for Health Care
Professionals. November 26th, 9:15, 2004, Feldkirch, Austria

Melanoma Prevention. First Vorarlberg Skin Caring Day for Health Care
Professionals. November 26th, 15:45, 2004, Feldkirch, Austria

DERM-OCC II – Phase 1 and 2. Presentation of results, follow-up activities, full
company roll out. Board of Directors presentation, Austrian Mineral Oil
Association (OMV), Friday 26th of November, 2004, OMV International Headquaters,
Vienna, Austria.

Sexually transmitted diseases. Post-graduate Training Program for Physicians.
Thursday January 13th 2005, Feldkirch, Austria
12
Strohal – 7/2006

Immunology, Epidemiology and Prevention. Typ-1 allergies in pediatric patients.
Symposium and Workshop Society of Physicians Vorarlberg, Saturday January
15th, 9:00 am – 16:00 pm, 2005, Dornbirn, Austria

Coronary and Atherosclerosis/peripheral arterial occlusion disease. A scientific and
clinical symposium. Co-organization and chair. Society of Physicians Vorarlberg
and VIVIT Research Institute. Saturday 26th of February, 8:30am – 2:00pm, Federal
Academic Hospital in Feldkirch, Austria

Biologicals – a new generation of drugs in medicine. Symposium lecture, Society of
Physicians Vorarlberg, Friday March 18th, 7:30 pm, 2005, Dornbirn, Austria

Toxic epidermal necrolysis. Post-graduate Training Program for Physicians.
Thursday March 31th 2004, Feldkirch, Austria

MRSA – strategies for de-colonization. Wound-Management Seminar. 43th Annual
Meeting of the German Dermatologic Society. April 20th - 22nd , 2005, Dresden,
Germany.

Allergies – who, what, when and is there a cure ? Lecture at the Annual Meeting of
the Nursing Association Koblach, April 28th, 2005. Koblach, Austria.

Out-door work as potential risk for melanoma. EADO Symposium at the 10th World
Congress on Cancers of the Skin. May 13th – 16th, 2005, Vienna, Austria.

Putting promise into practice: Biologics in the treatment of psoriasis. EADV Satellite
Symposium “Biologic Therapy” at the 3rd EADV Spring Symposium, May 20th, 2005,
Sofia, Bulgaria.

Biologics in Dermatology. 13. Salzburger Therapiegespräche, ÖADF, May 27th,
2005, Mondsee, Austria.

Allergies – who, what, when and is there a cure ? Evening lecture for the UNIQA
Health Care Club for Private Patients, June 7th, 2005, Feldkirch, Austria.

The concept of local MRSA management. Invited Series of Lectures, S+N
Academy, September 7th – 10th, 2005, Lunch and Dinner Meetings in Calgary,
Winnipeg, Toronto, Ottawa, Montreal and Halifax, Canada.

Management strategies for Psoriasis. Invited Biologics Lecture Series, Wyeth
International: A review of the established treatment paradigm (Hong Kong Society of
Family Physicians); An introduction to etanercept (press conference); Biologic
therapies in the management of psoriasis (Hong Kong Society of Dermatologists)
September 13nd – 14nd, 2005, Hong Kong, China.

The problem of aged skin. Lecture at the Weekly Meeting of the Roman Catholic
Aged Community in Tisis, September 15th, 2005. Feldkirch, Austria.

Biological Therapies in Psoriasis and Psoriatic Arthritis. Eastern-European Kick-off
Meeting, Wyeth International, September 19th, 2005. Vienna, Austria

Nanocristalline silver dressings and MRSA. Symposium, Annual Meeting of the
Italian Society of Wound Care, September 22nd, Turin, Italy.

A new dawn for the molecular biological research in Vorarlberg – New results of the
VIVIT Institute. Closing remarks, VIVIT Institute and Society of Physicians
Vorarlberg, September 28th, 2005, Dornbirn, Austria
13
Strohal – 7/2006

Local MRSA management – a new solution to an increasing problem. Symposium
Lecture at the Nordic Scientific Meeting on Wound Healing. October 6th, 2005,
Kopenhagen, Denmark.

Out-door work as potential risk for melanoma. Lecture and Chair of the EADO
Sister Society Symposium at the 14th EADV Congress. October 12th, 2005,
London UK.

The role of Humira in psoriasis arthritis – a survey with dermatologists. Presentation
at the kick-off meeting of the Austrian Advisory Board “Humira and Psoriasis
Arthritis”, November 11th, 2005, Vienna, Austria.

Stones of the biliary duct – what to do ? Welcome reception. 1st InternetVideoconference Society of Physicians Vorarlberg with the Society of
Physicians Vienna, November 9th, 7:00 pm, 2005, Feldkirch and Vienna, Austria

Protopic-Patch – The impact of Tacrolimus 0,1% on the nickel-positiv patch test.
Astellas Symposium “ Protopic - from Bench to Bed side” at the Annual Meeting of
the Austrian Society of Dermatology and Venerology, November 26th, 2005,
Vienna, Austria.

Biological Therapies in Psoriasis and Psoriatic Arthritis. Symposium Lecture,
Slowakien Teaching Symposium on the use of Etanecept in Psoriasis and
Psoriasis Arthritis. Wyeth Slawakia and Austria, 3.12.2005, Bratislawa, Slowakia.

Allergies – their impact, role and how to treat them. Lions Club Evening, January 4th,
2006, Feldkirch, Austria.

The structure of skin lesions. Post-graduate Training Program for Physicians.
January 19th 2005, Feldkirch, Austria

DERM-OCC – a new prevention and security concept for the industry. January 24th ,
2006. Invited lecture at HILTI International Inc., Schaan, Liechtenstein.
What is new on a global scale. Presentation and Co-Chair of the Austrian “Enbrel in
Psoriasis and Psoriasisarthritis” Advisory Board, Wyeth Whytehall Inc., February
2nd 2006, Vienna, Austria.
Ulcus cruris and strategies for the MRSA decolonisation. Plenary Lecture, 2nd
Munich Interdisciplinary Symposium on Wound Healing. March 10th 2006,
Munich, Germany.
The Medical Approach to Chronic Wounds. Quality Circle of the Family Doctors,
March 16th, 2006, Bregenz, Austria.
Development of New Skin Care Standards for the Industry. Invited Lecture at
Stockhausen-Degussa. March 21st, 2006. Krefeld, Germany.
Strategies for the MRSA decolonisation of wounds. Plenary Lecture, 1st
Interdisciplinary Wound Symposium. April 1st 2006, Mainz, Germany.
Development and Implementation of Process oriented Skin safety Standards for the
Mineral Oil Industry: A Pilot Study. Presentation at the Human Factors Symposium of
the 8th International Conference on Health, Safety and Environement. Society of
Petrol Engineers, April 3rd 2006, Abu Dhabi, Arab Emirates.







Sun – that´s okay, but please do it right. Evening lecture for the UNIQA Health Care
Club, April 6th, 2006, Feldkirch, Austria.
14
Strohal – 7/2006

Local MRSA management of acute and chronic wounds – What is next. Invited
lecture at the Strategic Meeting for Silver in the Field of Infection Control. Smith
+ Nephew Headquaters, April 13th, 2006, Hull, UK.

Sun and Skin Cancer – a dangerous partnership. Public Lecture for the Cancer-AID
Society, Section Vorarlberg, May 4th, 2006, Frastanz, Austria.

Optimising the management of psoriasis with biologics – Lecture and New insights
into the use of Etanercept – Workshop. Second Enbrel Psoriasis Summit of the
Middle East and North Africa: Raising the bar in psoriasis treatment. May 11th,
2006, Cairo, Cairo, Egypt.

Definition and Implementation of work-phase adapted skin protection measures for
the oil and gas industry – a pilot study. 8th International Skin Protection Day, May
16th, 2006, Krefeld, Germany.

The skin – a specific coat for our body and soul. MINIMED Teaching Series. June
6th, 2006, Wolfurt, Austria.
Local MRSA management: A new solution to an increasing problem. Plenary Lecture,
Meeting of the Polish Burn Society. June 9th 2006, Poznan, Poland.
Out-door work as potential risk for melanoma ? Invited Lecture and Chair of Session:
Free Communication Part II. 3rd Meeting of the European Association of DermatoOncology (EADO). June 23-25, 2006, Rome, Italy.


 Consultant Work

European Commission - 5th and 6th EU Framework-Programme:
-
Selected by the European Commission as member and raporteur of the “2000
Monitorinq panel für the Quality of Life Programme"; 11/00 - 6/01, Contract N°
QLEV-2000-22630.
-
Expert (Reference N° EE19981AO0287) for the evaluation of RTD applications
in several different areas and calls of the fp5 Quality of Life programme:
Contract N° QLEV-CT99-00016 - Accompanying Measures (5/99); Contract N°
QLEV-CT99-01040 - Generic Activities, Area 7.1, Chronic and Degenerative
Diseases (7/99); Contract N° QLEV-CT99-01616 - final panel of Area 7.1,
Chronic and Degenerative Diseases (7/99); Contract N° QLEV-1999- 08793 Generic Activities, Area 7.2 and 7.3, Chronic and Degenerative Diseases (1/00);
Contract N° QLEV-2000-20063 - chairman-rapporteur immunology/cancer of the
final panel Area 7.2 and 7.3, Chronic and Degenerative Diseases (1-2/00);
Contract N° QLEV-2000-22342 Accompanying Measures (7/00); Contract N°
QLEV-2000-26716 – Generic Activities, Area 7.1, Chronic and Degenerative
Diseases (11/00); Contract N° QLEV-2000-26406 - Key Action 3, Area 3.1 and
3.2 (12/00); Contract N° QLEV-2000-28614 - final panel of Area 7.1, Chronic
and Degenerative Diseases (12/00).
-
Expert (Reference N° EE19981AO0287) for the assessment and ranking of
applications in the Expression of Interest (Eol) Call of the upcoming new fp6,
Contract N° QLEV-2002-23930 (6/02).
-
Expert (Reference N° EE19981AO0287) for the evaluation of projects - midterm reviews: 26.3.04 Project QLG1-2002-01738, Contract letter CTEX2002B014436-101;
15
Strohal – 7/2006












Procter & Gamble Inc. (1998 - 2001):
-
Review of and answers to professional and consumer health-related product
inquires in Austria, 1998 - 2000.
-
Clearasil Complete: Assistance in the generation of scientific objectives and
strategies für a marketing project to address Austrian dermatologists and GPs.
Assistance in the development of the broschure "Life - Unsere Haut" (target
group: consumers age 12 - 20)
-
SECRET - Preparation of a broschure für the European market with
professional health care workers as target group. Elected by Procter & Gable as
the single best approach for roll-out across Europe.
-
Menopause and the skin - ProVital: Consultant work für the global Unit of
Procter & Gamble (GBU-EGHAM-UK) to develop strategies and scientific
objectives for a world-wide marketing programme on the basis of the "Austrian
Gynaecologist Model" (brochure, skin manual, scientific product profile)
-
Charming - bath paper: Evaluation and Review of pre-market skin-safety
studies.
Health Consult Inc. - Center of Occupational Medicine and Medical Consulting
(1996 – 2002):
-
Development of DERM-OCC: a dermatological survey programm specifically
designed für the occupational medicine needs of industrial companies larger
than 300 employees.
-
Melanoma prevention programme
-
Dermatological assistance for physicians in the field of occupational medicine
American Academy of Dermatology: Designated as formal observer for the 62nd
Annual Meeting, February 6th – 11th, 2004, Washington DC, USA
OMV – Austrian Mineral Oil Assotiation: medical consultancy in form of cooperation
projects - Dermatology and occupational medicine, start 10/00Smith + Nephew GmbH: strategic consultancy, cooperate clinical scientist (e.g.
training network for medical doctors, medical marketing aspects), start 9/02Wyeth Lederle Pharma: strategic consultancy, start 9/03Sanova Inc. Austria: strategic consultancy, start 2/04Serono Inc. Austria: strategic consultancy, start 9/04Abott Inc. Austria: strategic consultancy, start 8/05Helbo Photodynamic Lasersystems International: strategic consultancy, start
9/05Ucb Pharma GmbH Austria: strategic consultancy, start 2/063M-Woundcare GmbH Austria: strategic consultancy, start 5/06-
 Original articles

R. KOFLER, D.J. NOONAN, R. STROHAL, R.S. BALDERAS, N.P.H. MOLLER, F.J
DIXON and A.N. THEOFILOPOULOS. Molecular analysis of the murine lupus
associated anti-self response: Involvement of a large number of heavy and light chain
variable region genes. Eur.J.lmmunol. (1987) 17:91-95
16
Strohal – 7/2006

G. KRÖMER, R. FÄSSLER, R. STROHAL, G. WICK and R. KOFLER. Evidence for a
new murine immunglobuline heavy chain variable region gene family.
Immunol.lnvestigations (1986) 16:107-116

R. STROHAL, G. KRÖMER, G. WICK and R. KOFLER. Complete variable region
sequence of a non-functionally rearranged kappa light chain transcribed in the nonsecretor P3-X63-Ag8.653 myeloma ceilline. Nucleic Acid Research (1987) 15:2771

R. KOFLER, M.A. DUCHOSAL, M.E. JOHNSON, M.T. AGUADO, R. STROHAL,
G.KRÖMER and R. FÄSSLER. The genetic origin of murine Lupus-associated
autoantibodies. Immunol.Letters (1987) 16:265-272

R. KOFLER, R. STROHAL, R.S. BALDERAS, M.E. JOHNSON, D.J. NOONAN, M.A.
DUCHOSAL, F .J. DIXON and A.N. THEOFILOPOULOS. Ig germline gene
organization and Ig genes expressed in anti-DNA autoantibodies from lupus mice.
J.Clin.lnvest. (1988) 82:852-860

R. STROHAL, G. KROEMER, H. WOLF, G. WICK and R. KOFLER. Molecular
analysis of the Lupus-associated anti-self immune response. Wi.Kli.Wo. (1988)
23:753-760

R. STROHAL, A. HELMBERG, G. KROEMER and R. KOFLER. Mouse Vk gene
classification by nucleic acid sequence similarity.lmmunogenetics (1989) 30:475-493

R. STROHAL, R. GILLITZER, E. ZONZITS and G. STINGL. Localized vs. generalized
pyogenic granuloma: A clinicopathological study. Arch.Dermatol. (1991)
127:856-861

ELBE, O. KILGUS, R. STROHAL, E. PA YER, S. SCHREIBER and G. STINGL. Fetal
skin: a site of dentritic epidermal T Cell developement. J.lmmunol. (1992) 149:16941701

E. PAYER, R. STROHAL, R. KUTIL, A. ELBE and G. STINGL. Demonstration of a
CD3+ Iymphocyte subset in the epidermis of athymic nude mice: evidence für TCR diversity. J. Immunol. (1992) 149:413-420

R. STROHAL, K. RAPPERSBERGER, H. PEHAMBERGER and K. WOLFF. Nonbullous pemphigoid: Prodrome of bullous pemphigoid or a distinct pemphigoid
variant? J.Am.Acad.Dermatol. (1993), 29:293-299

O. KILGUS, E. PA YER, S. SCHREIBER, A. ELBE, R. STROHAL and G. STINGL. Invivo cytokine expression in normal and perturbed murine skin - analysis by
competitive quantitative polymerase chain reaction. J.lnvest.Dermatol. (1993)
100:674-680

R. STROHAL, L. PAUCZ, H. PEHAMBERGER and G. STINGL. T -Cell receptor
repertoire of Iymphocytes infiltrating cutaneous melanoma is predominated by V
specificities present in normal human skin. Cancer Research (1994) 54:4734-4739

R. STROHAL, K. MARBERGER, H. PEHAMBERGER and G. STINGL.
Immunhistological analysis of anti-melanoma host responses. Arch.Derm.Res.
(1994), 287:28-35

F. TRAUTINGER, C. JANTSCHITSCH, R. STROHAL, M. POURMOJIB and I.
KINDAS-MÜGGE. Mispriming and PCR amplification of hsp27. Cell Stress &
Chaperones (1998), 2:276-277
17
Strohal – 7/2006

R. STROHAL, CH. BRNA, U. MOSSBACHER, G. FISCHER, H. PEHAMBERGER
and G. STINGL. First comparative delineation of the T -Cell receptor repertoire in
primary and multiple subsequent/coexisting metastatic melanoma sites. J. Invest.
Dermatol. (1998),111:1085-1091.

R. STROHAL, E. TSCHACHLER, S. BREYER, A. UTHMAN, I. SIMONITSCH, S.
TRATTNIG, W. SCHEITHAUER, G. STINGL and G.V. KORNEK. Reactivation of
Behyet's disease in the course of a multicentric HHV8-positive Castleman's disease:
long-term complete remission by a combined chemo/radiation and Interferon-
therapy regimen. Brit. J. Haematol. (1998), 103:788-790.

R. STROHAL and G. STINGL. What is the best way to define the anti-melanocyte Tcell repertoire? J. Invest. Dermatol. (1999), 113:286-288.

R. STROHAL, R. MOSSER, H. KITTLER, K. WOLFF, B. JANSEN, C. BRNA, G.
STINGL, and H. PEHAMBERGER. Comparative PCR analyses of MART -1/Melan-A
and tyrosinase mRNA expression in peripheral blood of stage I-IV melanoma
patients. Melanoma Research, (2001), 11: 543-548.

DORIAN WINTER, EDDA FIEBIGER, PAUL MERANER, HERBERT AUER,
CHRISTINE BRNA, ROBERT STROHAL, FRANZ TRAUTINGER, ROBERT
KNOBLER, GOTTFRIED F. FISCHER, GEORG STINGL, and DIETER MAURER.
Definition of T Cell receptor epitopes für cytotoxic T -Iymphocyte-mediated attack of
cutaneous lymphoma. J. Immunol., (2003), 171: 2714

ASTRID BREUß, CAROLA WOLBER, JOHANNES ROTHMUND and ROBERT
STROHAL. Mycobakteriosis with atypical course? pneumologisch, (2003), 4: 22.

CLAUDIA SCHIESSL, CAROLA WOLBER AND ROBERT STROHAL. Reproducibility
of patch tests: Comparison of identical test allergens from different commercial
sources. Contact Dermatitis, (2004), 50: 27-30.

CAROLA WOLBER; FELIX OFFNER AND ROBERT STROHAL. Therapieresistente
zentrofaziale Schwellung im Jugendalter. Jartros Dermatologie, 1:42-43 (2004)

CLAUDIA SCHIESSL AND ROBERT STROHAL. Reply: Reproducibility of patch
tests. Contact Dermatitis, 51: 45-46 (2004)

WALTER RHOMBERG, HELMUT EITER, FRANZ BOEHLER, CHRISTIAN SAELY,
AND ROBERT STROHAL. Combined Razoxane and Radiotherapy for Melanoma
Brain Metastases: a retrospective study. Journal of Neuro-Oncology, 74: 295-299
(2005).

ACHIM SCHNEEBERGER, TAMARA JANDL, FRIEDER KOSZIK, ...... KLEMENS
RAPPERSBERGER, ROBERT STROHAL, ...... GEORG STINGL. S100B and
Melanoma Inhibitory Activity (MIA) Production Rates Differ Among Primary human
Melanoma Lines – Implications for their Use As Melanoma Markers. submitted for
publication (2006).

ROBERT STROHAL, MARC SCHELLING, MICHAEL TAKACS, WOLFGANG
JUREKA, ULRIKE GRUBER AND FELIX OFFNER. Nanocrystalline silver dressings
as an efficient anti-MRSA barrier: a new solution to an increasing problem. Journal of
Hospital Infection, 60:226-230 (2005)

CLAUDIA SCHIESSL, CAROLA WOLBER, MARTINA TAUBER, FELIX OFFNER,
AND ROBERT STROHAL. 5% Imiquimod cream for the treatment of basal cell
carcinoma – A follow-up study. submitted for publication (2006).
18
Strohal – 7/2006

NIKOLE SPEISER-RANKINE, WERNER UNTERBERGER, RUDOLF TAIBL, GABI
PAYER-NEUNDLINGER; MARTINA MITTLBÖCK AND ROBERT STROHAL.
Development and implementation of process-oriented skin safety standards for the
mineral oil industry – a pilot study. Society of Petrol Engineers Journal, Nr. 98731,
April 2006.

W.H. BÖHNKE, R.A. BRASIE, J. BARKER, S. CHIMENTI, E. DAUDÉN, M. DE RIE,
L. DUBERTRET, A. GIANETTI, A. KATSAMBAS, K. KRAGBALLE, J.M. NAEYAERT,
J.P. ORTONNE, J. PEYRI, J.C. PRINZ, J.H. SAURAT, R. STROHAL, P. VAN DER
KWERKHOF, W. STERRY.
Recommendations for the use of etanercept in
psoriasis: a European Dermatology Expert group consensus. Journal of the
European Academy of Dermatology. In press (2006).

ROBERT STROHAL, MARC SCHELLING, MICHAEL TAKACS, WOLFGANG
JUREKA, ULRIKE GRUBER AND FELIX OFFNER. Opatrunki z nanokryztalami
srebra jako skuteczna bariera przeciwko szczepom MRSA: nowy sposób na
rozwiązanie rosnącego problemu. Leczenie Ran 3(S2): S29-S33 (reprint in Polish
from the Journal of Hospital Infection, 60:226-230, 2005. Nanocrystalline silver
dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem)
 Reviews and bock chapters

G. KRÖMER, R. STROHAL, R. FÄSSLER, G. WICK, D.J. NOONAN, F.J. DIXON,
A.N. THEOFILOPOULOS and R. KOFLER. Cloning and sequencing of murine lupusassociated autoantibody genes. In: The Influence of New Technology and Medical
Practice J.P.Paul, Ed. Macmillan Publishers Ltd., London (1986) 225-248

R. STROHAL, H. WOLF and R. KOFLER. Molekulargenetische Analyse der
Autoantikörper-Produktion bei systemischem Lupus erythematodes. Extracta Derm.
(1989) 3:156-157

G. STINGL, A. ELBE, E. PAYER, O. KILGUS, R. STROHAL and S. SCHREIBER.
The role of fetal epithelial tissues in the maturation/differentiation of bane marrowderived precursors into dendritic epidermal T -cells (DETC) of the mouse. ln: Current
Topics in Microbiology and Immunology. Springer Verlag Berlin, Heidelberg (1991)
173:269-277

R. STROHAL, R. GILLITZER, E. ZONZITS and G. STINGL. Generalized pyogenic
granuloma Dermatoloqy Digest (1992) 2:6-7

R. STROHAL. Localized vs generalized pyogenic granuloma. Clinical Digest Series
(1992) 12:808-809

MICHITSCH, R. STROHAL, W. OSTERODE, CH. WOLF und B. ORTEL. Ein Fall von
Plumboporphyrie als Beispiel für die Grenzwertproblematik in der Arbeitsmedizin. In:
Gentoxische Substanzen in der Arbeitswelt, Editor: E. Baumgartner; Austrian Society
of Industrial Medicine; Verlag Wilhelm Maudrich, Wien, München (1995), 20-22

CH. WOLF, G. MÄNNER, S. MEGHDADI, A. MICHITSCH und R. STROHAL. Fieber
durch inhalative Noxen: Seltene Ursachen. Atemw.Lunqenkrkh. (1995) 21 :S70-S71
(1. Suppl.)

G. KOFLER, I. MOSCHEN, E. TSCHACHLER und R. STROHAL. Die Bedeutung von
HIV in der Zahn-, Mund- und Kieferheilkunde: Ein virologisches, epidemiologisches
und klinisches Update mit besonderer Berücksichtigung der HIV Infektionsprophylaxe
19
Strohal – 7/2006
und postexpositioneller Prävention. Stomatologie (1997), 94:345-362 and Deutsche
Zahnärztliche Zeitschrift (1997), 52:586-596

G. KOFLER, I. MOSCHEN, E. TSCHACHLER und R. STROHAL. Die Bedeutung von
HIV in der Zahn-, Mund- und Kieferheilkunde: Ein virologisches, epidemiologisches
und klinisches Update. Schweizer Monatsschrift für Zahnmedizin (1997) 107:1-9

R. STROHAL. Melanom Antigene. Onkoloqisch - Aktuelles für die Praxis (1998)

R. STROHAL. Wieviel Wirkkosmetik braucht der Mensch? In: HAGE III - Wohin geht
die kosmetische Industrie im neuen Millenium ? IMUG Eigenverlag Hannover (2001),
12-16

SCHNEEBERGER, R. STROHAL and G. STINGL. Das maligne Melanom. In:
Klinische Onkologie, Editoren: H. Huber, W. Hiddemann, C.R. Bartram Springer
Verlag Berlin, Heidelberg (2003), chapter 65: 1553-1602
 Books/other Publications

Christian WEINBERGER AND ROBERT STROHAL. SECRET - Produktmonographie.
Procter & Gamble Austria, Medizinisch-Wissenschaftliche Abteilung, Wien (1999)

JOHN GRAY AND ROBERT STROHAL. Die Haut im Rahmen des Peri/post
menopausalen Symptomenkomplexes: Eine kosmetische Herausforderung. Procter &
Gamble International, GBU, EGHAM, London (2000)

The Year 2000 Monitoring Panel of external experts (ROBERT STROHAL RAPPORTEUR, MIRIAM WILEY - RAPPORTEUR, JOHN DAVISON-RAPPORTEUR,
CORNELIS DE WINTER, JYRKI LIESIVUORI, HELEN SAVAKI, FRIEDRICH
WEISSBACH, und DANIEL THOMAS - CHAIRMAN). 2000 Annual monitoring report
on the RTD activities conducted under the European Commission "Quality of life and
management of living resources" programme. Office for official publications of the
European Communities, Luxenbourg (2001)

ROBERT STROHAL. Dermatologie und Venerologie in Vorarlberg, Jartros
Dermatologie, (2002) 6:28

K. WOLFF, ....., R. STROHAL, ...., B. VOLC-PLATZER. Alefacept – ein neuer
immunmodulierender Therapieansatz in der Behandlung der Psoriasis. Consensus Statement. Update, (2003), 14: 1-14

P. FRITSCH, ....., R. STROHAL, ...., B. VOLC-PLATZER. Stellenwert von
Tacrolimus-Salbe (Protopic) in der Behandlung der atopischen Dermatitis. Experts Statement. Update, (2004), 31:1-16

G. STINGL, R. STROHAL, ...., W.F. STERRY...., UND B. VOLC-PLATZER.
Stellenwert von Etanercept in der Therapie der Psoriasis und Psoriasisarthritis.
Konsensus - Statement. Update, 41:1-19, 2004

G. STINGL, W. ABERER, ...., R. STROHAL...., UND K. WOLFF. Stellenwert von
Efalizumab in der Behandlung der Psoriasis. Consensus - Statement. Update, 21:120, 2005.

W. ABERER, P. FRITSCH, HJ. RAUCH, G.STINGL UND R. STROHAL.
Positionspapier Behandlung der Psoriasis mit Biologika. Update, 1: 1-11, 2006.

R. STINGL, A. REYNOLDS, S. CHIMENTI AND R. STROHAL.
20
Strohal – 7/2006
Etanercept: The future of the psoriasis therapy – A Advisory Board Report. pp 1-6,
January, 2006.
 Community Relations and Media Work

Sun without Remorse, Awareness Day by the ÖGDV and Österreichische
Krebshilfe, May 5, 2002,
programme for the province of Vorarlberg: out-door occupation and melanoma
risks,
teaching day für primary school children, free evaluation of moles at the Dept. of
Dermatology, Federal Academic Hospital of Feldkirch

Radio Arabella:
-
Radio interview "Radio Arabella" - Melanoma Prevention –
Awareness day, 7.5.2003

Austrian Broadcast Radio – Radio Vorarlberg:
-
60 min. Hotline (Aktuelles Thema), April 4, 2002
-
News of the day, Interview Bienen/Wespengiftallergien, May 14, 2003
-
News of the day, Sun without Remorse, Awareness Day, May 19, 2003
-
Sexually transmitted diseases, July 18, 2003
-
News of the day, Sun without Remorse, Awareness Week, May 25, 2004
-
60 min. Hotline (Aktuelles Thema), May 27, 2004
-
Feet-associated fungal infections, Bodenseemagazin, 28.2.2005
-
Sun and Skin. 60 min. Hotline (Aktuelles Thema), May 24, 2005
-
News of the day, Concerted Action Felsenau, July 2, 2005
-
60 min. Hotline (Aktuelles Thema), January 11, 2006 (report, cold weather
and the skin)
-
Botox and the dream of eternal youth. 60 min. Hotline (Aktuelles Thema),
March 27, 2006 (report, cold weather and the skin)
-
Sun and Skin Cancer. 60 min. Hotline (Aktuelles Thema), May 15, 2006
-
-

Silver as potent anti-microbial agent, Report Series: World of Science,
December 20, 2004
Austrian Broadcast Radio – Ö1:
-

Report, Morning News, Hot days and the skin, July 20, 2006
Austrian Broadcast Radio – Ö1:
-

Report, Morning News, Skin cancer check at the public bath Felsenau –
Results, June 7, 2006
The plant Bärenklau and the danger of phototoxic reactions. Report,
Breakfast News, May 23rd, 2006
Antenne Vienna Radio:
21
Strohal – 7/2006
-

Austrian Broadcast Television – Section Vorarlberg (Vorarlberg heute):
-
Report, Interview "General Dermatology"- March 3, 2002
-
Report, Interview "Increasing Allergies" - April 24, 2002
-
Report, Studio Discussion "Melanoma Prevention" . May 6, 2002
-
Report, Sun without Remorse, Awareness Day, May 19, 2003
-
Report, DERM-OCC – the project, September 17, 2003
-
Report, Dangers of the sun in the mountains, March 17, 2004
-
Report, Sun allergies, April 2, 2004
-
Report, Sun without Remorse, Awareness Week, May 26, 2004
-
Report, Sun without Remorse, Awareness Week, May 18, 2005
-

Report, Concerted Action at the public bath Felsenau – Impressions,
Results, July 2, 2005
Sat-1/Austrian Television Window:
-

Morgenjournal und Drive-Time – Beitrag: Schwitzen, was kann ich dagegen
tun, August 5, 2003
Health today: Report, Interview "Biologicals for Psoriasis"- October 27th,
2004
BBC-News online
- Silver dressings to fight MRSA,
(http://news.bbc.co.uk/1/hi/health/4172207.stm), 18.1.2005
 Austrian Broadcast Television online – www.orf.at
- Sun and the skin, 60 minutes Chat, 24.5.2005
 Vorarlberger Nachrichten:
- Headline News: - Strong increase of atopic dermatitis – new therapeutic
options, September 25, 2002
- Ask your specialist on the phone, General Dermatology, October 10,
2002Hay fever - new therapeutic options, 18.4.2003
-
Melanoma Prevention - Awareness day, Reports April 22, 24, 25, 28 and
May 15, 19, 2003
-
Ask your specialist on the phone, Sun and Skin, April 25, 2003
-
Melanoma Prevention - Awareness week, Report, May 26, 2003
-
Ask your specialist on the phone, Sun and Skin, June 21, 2004
-
Dermatological problems of the summer, Interview, June 23, 2004
-
Skin and signs of internal diseases, Report, March 4, 2005
-
Ask your specialist on the phone, Allegies and atopic ekzema, March 19, 22,
24, 2005
„Let your spots be checked”, Interview, May 26/27, 2005
Progress on the track, Report, June 3, 2005
„Safer Sun“ for those who love the sun, Interview, June 24, 2005
-
22
Strohal – 7/2006
-
Mole-check at the public swimmingpool Felsenau in Feldkirch, Report, July
4, 2005
The dangers of dry cold, Report November 29, 2005
Red cheeks might be dangerous, Report, December 31, 2005
The early fight against the sun, Report, February 9, 2006
-
Sun and skin cancer, Reports May 25 and 27, 2006
-
Ask your specialist on the phone, Sun and skin cancer, May 29, 2.003.30pm, 2006.
-
-
-
-
-


Melanoma Prevention - Awareness day, Report 9.5.2003
-
Melanoma Prevention - Awareness day, Report 15.5.2003
-
Melanoma Prevention - Awareness day, Report June 14, 2004
Jartros Dermatologie:
Argentum ante portas. 3:16 (2003)
Forum Gesundheit:
-

Psoriasis and Therapy with Biologics, Report, StandardMed, August 14th,
2006.
Das kleine Blatt:
-

MINIMED Lecture Series: The skin – a specific coat for the body and soul.
Report of the Lecture Evening, June 10, 2006.
Wann und Wo weekly:
-

Awareness Action “sun:watch” at three public swimming pools in Vorarlberg
(Bludenz, Feldkirch, Bregenz). Report, June 9, 2006
Der Standard:
-

MINIMED Lecture Series: The skin – a specific coat for the body and soul.
Announcing report, June 3 and 6, 2006.
Wenn der Bart kehrt macht. 4:23 (2003)
Hautnah der Ärztewoche:
-
Studie zur AD-Schubprophylaxe. 4 (Jänner):27 (2005)

Dermatology Times:

Out-door work as potential risk for melanoma. May 2005, USA
Feldkircher Anzeiger

Sun without Remorse – 7 sun rules, Interview, May 20, 2005
NEUE Vorarlberger Tageszeitung
-
-
-
Bee sting reactions, Report, June 2, 2005
-
Sun burn: „like a knife in the skin“, Report, July 5, 2005
Awareness Action “sun:watch” at three public swimming pools in
Vorarlberg (Bludenz, Feldkirch, Bregenz). Report, June 9, 2006
Feldkirch aktuell
-

-
Sun:watch – Felsenau Feldkirch, Report, June 2005
23
Strohal – 7/2006
 Published Abstracts and Posterpresentations (selection)

R. KOFLER, R. STROHAL, H. STEINER, H. WOLF, G. WICK, D.J. NOONAN, F .J
DIXON and A.N. THEOFILOPOULOS. Structural genetic elements encoding murine
lupus-associated monoclonal autoantibodies. XVII. Treffen der Deutsche Gesellschaft
für Immunologie, 25.-28. September 1985, Göttingen, Deutschland. Immunobiol.
(1985),170:46

R. STROHAL, D.J. NOONAN, G. KRÖMER, G. WICK, F.J. DIXON, A.N.
THEOFILOPOULOS and R. KOFLER. Studies on the genetic origin of lupusassociated monoclonal autoantibodies. Gemeinschaftssitzung der Deutschen
Gesellschaft für Immunologie und der Societe Francaise d'lmmunologie, 20.-22.
November 1986, Strasbourg, Frankreich. Immunobiol. (1986),173:219-220

R. KOFLER, D.J. NOONAN, R. STROHAL, R. FÄSSLER, F .J. DIXON and A.N.
THEOFILOPOULOS. Restricted V but divers V genes encode murine Lupus anti
single stranded DNA autoantibodies. FASEB 71. Jahressitzung, 29. März - 2. April
1987, Washington, DC, USA. Federation Proceedings (1987) 46:6135

R. STROHAL, G. KRÖMER, R. KOFLER and G. WICK. Molecular analysis of the
lupus-associated anti-self immune response. Jahressitzung der Österreichischen
Gesellschaft für Biochemie und der Österreichischen Gesellschaft für Biologische
Chemie, 12.-14. September 1988, Innsbruck, Österreich. Hoppe-Seyler Biol.Chem.
(1988) 369:927

R. STROHAL, A. RIEGER, K. RAPPERSBERGER; H. PEHAMBERGER, K. WOLFF
and G. STINGL. Non-bullous pemphigoid: Prodrome of bullous pemphigoid or an
autonomous clinical entity? 4. Immundermatologisches Symposium, 21.-23.
September 1989, Amsterdam, Niederlande. J.lnvest.Dermatol. (1989) 93:309

A. ELBE, O. KILGUS, R. STROHAL, H. SCHINHAN and G. STINGL. Establishment
of a felline of putative CD3-precursors of dendritic epidermal T cells (DETC) from
fetal skin. FASEB Gemeinschaftssitzung, 4.-7. Juni 1990, New Orleans, Louisiana,
USA. FASEB Journal (1990) 4:A1736

R. STROHAL, A. ELBE, O. KILGUS and G. STINGL. Thy-1+ cells within fetal murine
skin fail to express functional CD3-associated T Cell receptors. Arbeitsgemeinschaft
Dermatologische Forschung, 9.-11. November 1990, Mannheim, Deutschland.
Arch.Derm.Res. (1990) 12:34

Jahrestagung der Österreichischen Gesellschaft für Dermatologie, 2.-9. Februar,
1991, Zürs am Arlberg, Österreich. Schriftum und Praxis (1991) 22:120-122

R. STROHAL, A. ELBE, O. KILGUS and G. STINGL Thy-1 + cells from fetal murine
skin fail to express functional CD3-associated T Cell receptors. FASEB
Gemeinschaftssitzung, 21.-25. April, 1991, Atlanta, Georgia, USA. FASEB Journal
(1991) 5:A7710
 O. KILGUS, A. ELBE, R. STROHAL, E. PAYER, S. SCHREIBER and G. STINGL. In-----vivo cytokine expression of adult vs. fetal skin. FASEB Gemeinschaftssitzung, 21.-25.
April, 1991, Atlanta, Georgia, USA. FASEB Journal (1991) 5:A1004
 O. KILGUS, A. ELBE, R. STROHAL, E. PAYER, S. SCHREIBER and G. STINGL. In----- vivo cytokine expression of adult vs. fetal skin. SID, USA. 1.-3. Mai, 1991, Seattle,
Washington, USA. J.lnvest.Dermatol. (1991) 96:609
24
Strohal – 7/2006

R. STROHAL, L. PAUCZ, J. FRIEDL, H. PEHAMBERGER and G.STINGL. T cell
receptor V repertoire in tumor-infiltrating Iymphocytes of cutaneous malignant
melanoma. Arbeitsgemeinschaft Dermatologische Forschung, 15.-17. November,
1991, Graz, Österreich. Arch.Derm.Res. (1991) 284: 23-24

R. STROHAL, L. PAUCZ, J. FRIEDL, H. PEHAMBERGER and G.STINGL. Evidence
for a limited T Cell receptor repertoire in tumor-infiltrating Iymphocytes of cutaneous
malignant melanoma. Molecular Pharmacology of the skin, 7.-9. Februar, 1992,
Berlin, Deutschland. J.lnvest.Dermatol. (1992) 97:826
 O. KILGUS, A. ELBE, R. STROHAL, E. PA YER, S. SCHREIBER and G. STINGL. In-----vivo cytokine expression as determined by quantitative PCR. Molecular
Pharmacology of the skin, 7.-9. Februar, 1992, Berlin, Deutschland.
J.lnvest.Dermatol. (1992) 97:820

R. STROHAL, L. PAUCZ, J. FRIEDL, H. PEHAMBERGER and G. STINGL. Analysis
of the T Cell receptor repertoire in tumor-infiltrating Iymphocytes of cutaneous
malignant melanoma. European Society für Dermatological Research, 4.-7. April,
1992, London, England. J.lnvest.Dermatol. (1992) 98:507

K. MARBERGER, R. STROHAL, H. PEHAMBERGER and G. STINGL. Phenotypic
analysis of the mononuclear cell infiltrate in primary and secondary malignant
melanoma. Arbeitsgemeinschaft Dermatologische Forschung, 13.-15 November,
1992, Mainz, Deutschland. Arch.Derm.Res. (1993) 285: 64

H. PEHAMBERGER, R. DORFNER, M. BINDER, R. STROHAL, K. WOLFF and G.
STINGL. Serum factors as marker of melanoma progression. Second Tricontinental
Meeting of the JSID, SID, und ESDR, 28.-31. Oktober, 1993, Kyoto, Japan.
J.lnvest.Dermatol. (1993) 98:446(A354)

R. STROHAL, L. PAUCZ, J. FRIEDL, H. PEHAMBERGER and G.STINGL. The T cell
receptor repertoire of Iymphocytes infiltrating cutaneous melanoma is predominated
by V specificities present in T -cells of normal skin. The Second Tricontinental
Meeting of the JSID, SID, und ESDR, 28.-31. Oktober, 1993, Kyoto, Japan.
J.lnvest.Dermatol. (1993) 98:422(A207)

R. STROHAL, C. BRNA, H. ZAROUR, H. PEHAMBERGER and G. STINGL. A gp-1
00 TCR D chain is exclusively expressed in Iymphocytes infiltrating jung and
cutaneous metastases of three different melanoma patients presenting with multiple
gp-100/Mart-1 positive metastases. 57th Annual Meeting of the Society for
Investigative Dermatology, 1. - 5. Mai 1996, Washington DC, USA. J. Invest.
Dermatol. (1996) 106:928 (A737)

R. STROHAL, C. BRNA, H. PEHAMBERGER, U. MOSSBACHER, G. FISCHER, H.
ZAROUR and G. STINGL. Restricted usage of gp-1 OO-specific TCRBVDJ
transcripts associated with highly polymorphic CDR3 regions indicates the lack of
clonal expansion of tumor-reactive TIL in multiple gp-100-positive metastases of three
different melanoma patients. 25th Anniversary ESDR Meeting, 28. September - 1.
Oktober 1996, Amsterdam, Niederlande. J. Invest. Dermatol. (1996) 107:456 (A53)

R. STROHAL, C. BRNA, U. MOSSBACHER, G. FISCHER, H. ZAROUR, H.
PEHAMBERGER and G. STINGL. In-situ identification of al ready published Mart1/Melan-A and gp1 OO-specific T –cell receptor ß-chain genes in tumor-infiltrating
Iymphocytes of 12 Mart-1/Melan-A and gp100-expressing melanoma specimens from
3 non-HLA-A2 patients: Evidence for organ-specific CDR3 region expression in the
25
Strohal – 7/2006
context of highly conserved TCRBV J segments. 4th World Conference on
Melanoma, Concurrent Symposium, 10.-14. Juni 1997, Sydney Australien. Melanoma
Research (1997) 7 (Suppl. 1): S10

R. STROHAL, C. BRNA, U. MOSSBACHER, G. FISCHER, H. ZAROUR, H.
PEHAMBERGER and G. STINGL. In-situ identification of already published Mart1/Melan-A and gp100-specific T -cell receptor -chain genes in tumor-infiltrating
Iymphocytes of 12 Mart-1/Melan-Aand gp100-expressing melanoma specimens from
3 non-HLA-A2 patients: Evidence for organ-specific CDR3 region expression in the
context of highly conserved TCRBVJ segments. 19th World Congress of
Dermatology, 15. - 20. Juni 1997 Sydney, Australien. Australian J. of Dermatol.
(1997)

C. WOLBER, B. FEUERSTEIN, F. OFFNER, and R. STROHAL. Imiquimod-induced
CD4+ T –cell responses lead to lang lasting erythema after regression of basal-cell
carcinomas and actinic keratoses. 4th Joint Meeting of the JSID, SID and ESDR
(Tricontinental Meeting, April 30 - May 4,2003, Miami, Florida USA. J. Invest.
Dermatol.

R. STROHAL, G. HARTMANN, U. GRUBER, AND F. OFFNER. Efficient anti-MRSA
barrier and Iytic action of nanocrystalline silver dressings - a preclinical, in-vitro study.
4th Joint Meeting of the JSID, SID and ESDR (Tricontinental Meeting, April 30 - May
4, 2003, Miami, Florida USA. J. Invest. Dermatol., 2003

R. STROHAL, Basal Cell Carcinoma up-date, Schrifttum und Praxis, in press, 2006.

R. STROHAL, WERNER UNTERBERGER, MARTINA MITTLBÖCK AND GABI
PAYER-NEUNDLINGER. Out-door work as potential risk for melanoma ? 3rd Meeting
of the European Association of Dermato-Oncology (EADO). Abstract, J. Invest.
Dermatol. 126: S18, 2006.
Feldkirch, July 2006
26